Viral Diseases Tester Virax Biolabs Prices Upsized US$6.75 Million IPO

Biopharmaceutical company Virax Biolabs Group Limited recently increased its initial public offering size as it applies for a Nasdaq Capital Market listing. The firm is now looking to raise US$6.75 million.

The offering consists of 1.35 million common shares, up from the previously announced 1.2 million, selling at US$5.00 per share. The company targets to trade on the Nasdaq market under the symbol “VRAX”.

Boustead Securities acts as the sole bookrunner for the said offering. The underwriters were granted a 45-day over-allotment option to purchase additional 202,500 shares at the same IPO price.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Net proceeds from the offering are expected to be used for research & development, obtaining product certification approvals, expanding staff & payroll, marketing & advertising, working capital, operating expenses, inventory purchases, and regulatory & compliance work.

The UK-based biotech company focuses on developing T-cell testing as a method to detect one’s risk to major global viral threats through immunology profiling. The firm recently received ethical approval for its current study involving its Virax Immune COVID-19 test kit that bases its detection of viral immunity on T-cells instead of antibodies like most other kits.


Information for this briefing was found via Edgar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

HempFusion Files For US$17 Million Initial Public Offering

HempFusion Wellness, the CBD firm that caused much excitement last year when it conducted a...

Thursday, October 22, 2020, 10:32:49 AM

Circle Files for U.S. IPO to Bring Stablecoin USDC to Public Markets

Boston-based Circle Internet Financial, the driving force behind the widely-used stablecoin USDC, has confidentially filed...

Thursday, January 11, 2024, 09:29:00 AM

Chinese Biotech Firm LianBio Prices US$325 Million Nasdaq IPO

Biotech company LianBio (Nasdaq: LIAN) started trading on the Nasdaq Global Market today. The Shanghai-based...

Monday, November 1, 2021, 02:07:00 PM

Robinhood Stock Falls in First Trading Day After IPO; Still Looks Richly Valued

Robinhood Markets Inc. (NASDAQ: HOOD), the popular online brokerage which pioneered zero commissions for retail...

Friday, July 30, 2021, 02:32:00 PM

Internet Business SPAC Worldwide Webb Acquisition Prices US$200 Million IPO

Special purpose acquisition company Worldwide Webb Acquisition Corp. (Nasdaq: WWAC.U) started trading publicly on the...

Wednesday, October 20, 2021, 02:26:00 PM